A Prognostic Model for Bladder Cancer Based on Cytoskeleton-related Genes

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2023 Apr 28

PMID 37115085

Authors

Chunting Peng

Sufan Guo

Zheng Yang

Xiaohong Li

Qisheng Su

Wuning Mo

Affiliations

Soon will be listed here.

Abstract

Background: A typical cancerous growth in the urinary tract, bladder cancer (BLCA) has a dismal survival rate and a poor chance of being cured. The cytoskeleton has been shown to be tightly related to tumor invasion and metastasis. Nevertheless, the expression of genes associated with the cytoskeleton and their prognostic significance in BLCA remain unknown.

Methods: In our study, we performed differential expression analysis of cytoskeleton-related genes between BLCA versus normal bladder tissues. According to the outcomes of this analysis of differentially expressed genes, all BLCA cases doing nonnegative matrix decomposition clustering analysis be classified into different molecular subtypes and were subjected to Immune cell infiltration analysis. We then constructed a cytoskeleton-associated gene prediction model for BLCA, and performed risk score independent prognostic analysis and receiver operating characteristic curve analyses to evaluate and validate the prognostic value of the model. Furthermore, enrichment analysis, clinical correlation analysis of prognostic models, and immune cell correlation analysis were carried out.

Results: We identified 546 differentially expressed genes that are linked to the cytoskeleton, including 314 up-regulated genes and 232 down-regulated genes. All BLCA cases doing nonnegative matrix decomposition clustering analysis could be classified into 2 molecular subtypes, and we observed differences (P < .05) in C1 and C2 immune scores about 9 cell types. Next, we obtained 129 significantly expressed cytoskeleton-related genes. A final optimized model was constructed consisting of 11 cytoskeleton-related genes. Survival curves and risk assessment predicted the prognostic risk in both groups of patients with BLCA. Survival curves and receiver operating characteristic curves were used to evaluate and validate the prognostic value of the model. Significant enrichment pathways for cytoskeleton-associated genes in bladder cancer samples were explored by Gene set enrichment analysis enrichment analysis. After we obtained the risk scores, a clinical correlation analysis was performed to examine which clinical traits were related to the risk scores. Finally, we demonstrated a correlation between different immune cells.

Conclusion: Cytoskeleton-related genes have an important predictive value for BLCA, and the prognostic model we constructed may enable personalized treatment of BLCA.

Citing Articles

Investigation toward the economic feasibility of personalized medicine for healthcare service providers: the case of bladder cancer.

Savchenko E, Bunimovich-Mendrazitsky S Front Med (Lausanne). 2024; 11:1388685.

PMID: 38808135 PMC: 11130437. DOI: 10.3389/fmed.2024.1388685.

References

Ferro M, Vartolomei M, Cantiello F, Lucarelli G, Stasi S, Hurle R . High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study. Urol Int. 2018; 101(1):7-15. DOI: 10.1159/000490765. View

Miao Z, Ali A, Hu L, Zhao F, Yin C, Chen C . Microtubule actin cross-linking factor 1, a novel potential target in cancer. Cancer Sci. 2017; 108(10):1953-1958. PMC: 5623738. DOI: 10.1111/cas.13344. View

Yang J, Liu X, Dai G, Qu L, Tan B, Zhu B . CircNT5E promotes the proliferation and migration of bladder cancer via sponging miR-502-5p. J Cancer. 2021; 12(8):2430-2439. PMC: 7974885. DOI: 10.7150/jca.53385. View

Busetto G, Ferro M, Del Giudice F, Antonini G, Chung B, Sperduti I . The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non-muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2017; 15(4):e661-e666. DOI: 10.1016/j.clgc.2017.01.011. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Ferro M, Marchioni M, Lucarelli G, Vartolomei M, Soria F, Terracciano D . Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter study. Minerva Urol Nephrol. 2021; 73(6):796-802. DOI: 10.23736/S2724-6051.20.04076-X. View

Barone B, Calogero A, Scafuri L, Ferro M, Lucarelli G, Di Zazzo E . Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review. Cancers (Basel). 2022; 14(10). PMC: 9139497. DOI: 10.3390/cancers14102545. View

Izdebska M, Zielinska W, Halas-Wisniewska M, Grzanka A . Involvement of Actin and Actin-Binding Proteins in Carcinogenesis. Cells. 2020; 9(10). PMC: 7600575. DOI: 10.3390/cells9102245. View

Sahai E, Astsaturov I, Cukierman E, DeNardo D, Egeblad M, Evans R . A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020; 20(3):174-186. PMC: 7046529. DOI: 10.1038/s41568-019-0238-1. View

10.

Huang Y, Chen L, Guo A . Upregulated expression of HOXC8 is associated with poor prognosis of cervical cancer. Oncol Lett. 2018; 15(5):7291-7296. PMC: 5920507. DOI: 10.3892/ol.2018.8200. View

11.

Tsui K, Lin Y, Chang K, Hou C, Chen P, Feng T . Transgelin, a p53 and PTEN-Upregulated Gene, Inhibits the Cell Proliferation and Invasion of Human Bladder Carcinoma Cells in Vitro and in Vivo. Int J Mol Sci. 2019; 20(19). PMC: 6801752. DOI: 10.3390/ijms20194946. View

12.

Crocetto F, Barone B, Ferro M, Busetto G, La Civita E, Buonerba C . Liquid biopsy in bladder cancer: State of the art and future perspectives. Crit Rev Oncol Hematol. 2022; 170:103577. DOI: 10.1016/j.critrevonc.2022.103577. View

13.

Liu Y, Ding Y, Nie Y, Yang M . EMP1 Promotes the Proliferation and Invasion of Ovarian Cancer Cells Through Activating the MAPK Pathway. Onco Targets Ther. 2020; 13:2047-2055. PMC: 7071728. DOI: 10.2147/OTT.S240028. View

14.

Chen M, Nie Z, Cao H, Gao Y, Wen X, Zhang C . Rac3 Expression and its Clinicopathological Significance in Patients With Bladder Cancer. Pathol Oncol Res. 2021; 27:598460. PMC: 8262164. DOI: 10.3389/pore.2021.598460. View

15.

Ferro M, de Cobelli O, Musi G, Lucarelli G, Terracciano D, Pacella D . Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. Front Oncol. 2021; 11:651745. PMC: 8144638. DOI: 10.3389/fonc.2021.651745. View

16.

Wu J, Jiang J, Chen B, Wang K, Tang Y, Liang X . Plasticity of cancer cell invasion: Patterns and mechanisms. Transl Oncol. 2020; 14(1):100899. PMC: 7573380. DOI: 10.1016/j.tranon.2020.100899. View

17.

Du Y, Jiang X, Wang B, Cao J, Wang Y, Yu J . The cancer-associated fibroblasts related gene CALD1 is a prognostic biomarker and correlated with immune infiltration in bladder cancer. Cancer Cell Int. 2021; 21(1):283. PMC: 8164301. DOI: 10.1186/s12935-021-01896-x. View

18.

Piper M, Mueller A, Karam S . The interplay between cancer associated fibroblasts and immune cells in the context of radiation therapy. Mol Carcinog. 2020; 59(7):754-765. PMC: 8011858. DOI: 10.1002/mc.23205. View

19.

Ferro M, Tataru O, Musi G, Lucarelli G, Abu Farhan A, Cantiello F . Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin Immunotherapy. Diagnostics (Basel). 2022; 12(3). PMC: 8947693. DOI: 10.3390/diagnostics12030586. View

20.

Imai-Sumida M, Chiyomaru T, Majid S, Saini S, Nip H, Dahiya R . Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways. Oncotarget. 2017; 8(54):92032-92042. PMC: 5696161. DOI: 10.18632/oncotarget.20734. View